Effects of RAS inhibition on insulin sensitivity and IGF-I bioactivity

Completed

• Conditions: diabetes; diabetes mellitus; 10018424

• Registration Number: NL-OMON35702
• Lead Sponsor: Ikazia Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

- age 18 * 70 years
- impaired fasting glucose (IFG): fasting plasma glucose levels between 5,6 * 6,9 mmol/l (100 * 125 mg/dl) and/or impaired glucose tolerance (IGT): plasma glucose levels between 7,8 * 11,0 mmol/l (140 * 199 mg/dl) after 2 hours on the 75-g oral glucose tolerance test

Exclusion Criteria

- use of RAS inhibitors within 6 weeks prior to inclusion
- use of oral glucose-lowering drugs or insulin
- use of statins
- use of betablockers
- use of steroids, hormone replacement therapy or other study medication
- contraindication for or intolerant to RAS inhibitors
- untreated hypothyroidism or hyperthyroidism
- negroid race
- pregnancy and breastfeeding
- severe renal insufficiency (GFR < 30mL/min) and/or known bilateral renal artery stenosis
- hyperpotassemia (potassium > 5,0mmol/L)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary outcome will be the effect of short-term administration of the<br /><br>angiotensin-receptor antagonist losartan on insulin sensitivity, assessed by<br /><br>the baseline adjusted difference in the homeostasis model assessment of insulin<br /><br>resistance (HOMA) at eight weeks.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes will be the effect of short-term losartan treatment on total<br /><br>IGF-I and IGF-I bioactivity, and the correlation between changes in insulin<br /><br>sensitivity and changes in IGF-I system.</p><br>